Psychomotor therapy's effect on quality of life in depression
Influence of Psychomotor Therapy on Quality of Life in Patients With a Major Depressive Disorder: a Randomized Controlled Trial
This study tests if adding personalized psychomotor therapy to standard treatment can help improve the quality of life for people with major depressive disorder.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 128 (estimated) |
| Ages | 20 Years to 60 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Esquirol Academic / other |
| Locations | 1 site (Limoges) |
| Trial ID | NCT06234176 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of personalized psychomotor therapy in improving the quality of life for individuals diagnosed with major depressive disorder (MDD). Participants will be randomly assigned to receive either standard treatment alone or standard treatment plus weekly psychomotor therapy sessions for three months. The study aims to assess changes in quality of life and psychomotor profiles at three and six months. A total of 128 participants will be involved, with assessments focusing on various psychomotor skills and overall well-being.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 20 to 60 with a medical diagnosis of major depressive disorder and a Hamilton Depression Rating Scale (HDRS) score greater than 16.
Not a fit: Patients with psychiatric comorbidities, sensory impairments, or significant neurological conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life for patients suffering from major depressive disorder.
How similar studies have performed: While the effectiveness of psychomotor therapy in depression is not well-established, similar approaches have shown promise in improving patient outcomes in related fields.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of depressive episode according to DSM-5 criteria. * HDRS \> 16 * Hospitalized or followed-up in one of the participating centers. * Affiliated or beneficiary of a social security scheme. * Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research). Exclusion Criteria: * Psychiatric comorbidity (non-tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders) * Sensory impairment or proven neurological pathology * History of neurological brain damage (including stroke, tumor, trauma resulting in loss of consciousness lasting more than 10 minutes) * Limited functional ability (difficulty in moving about, performing manual tasks or moving about) * Inability to understand questionnaires and study information * Inability to travel to the inclusion center (personal vehicle, public transport) * Pregnant or breast-feeding women, on declaration * Forced hospitalization, subjects under guardianship or trusteeship, lack of social protection
Where this trial is running
Limoges
- CH Esquirol — Limoges, France (Recruiting)
Study contacts
- Study coordinator: Aude PAQUET, Dr
- Email: aude.paquet@ch-esquirol-limoges.fr
- Phone: +33555431127
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.